Lansoprazole
โน๏ธ About
Always check the BNF link here ๐ for the most up-to-date guidance.
- Oral dispersible โfast-tabโ format is useful for patients with swallowing difficulty or feeding tubes.
โ๏ธ Mode of Action
- Proton Pump Inhibitor (PPI) โ irreversibly inhibits the Hโบ/Kโบ ATPase in gastric parietal cells, suppressing gastric acid secretion.
๐ Indications & Dose
- Peptic ulcer disease / GORD / oesophagitis: 30 mg once or twice daily orally (PO) or sublingual (SL) for โฅ4 weeks.
- ZollingerโEllison syndrome: 60โ120 mg/day in divided doses, titrated to acid suppression.
- Oro-dispersible tablets: 15 mg or 30 mg once daily, dissolve on the tongue if appropriate.
- Can be given via large-bore enteral tube (flush well). โ Avoid fine-bore tubes (risk of blockage).
โ ๏ธ Interactions
- PPIs can reduce the antiplatelet effect of clopidogrel (particularly omeprazole, less so lansoprazole). โ ๏ธ
- May increase risk of phenytoin toxicity and alter absorption of other pH-dependent drugs.
- Occasional CNS effects reported (e.g. agitation, dizziness, impotence).
๐ Cautions
- See BNF โ use with care in severe liver disease, osteoporosis risk, and in patients on long-term therapy (risk of hypomagnesaemia, fractures, C. difficile infection).
๐ซ Contraindications
- See BNF โ hypersensitivity to lansoprazole, other substituted benzimidazoles, or excipients.
โ Side Effects
- Gastrointestinal: abdominal pain, constipation, diarrhoea, nausea, vomiting.
- Neurological: headache, dizziness, fatigue.
- Rare: hypomagnesaemia, interstitial nephritis, risk of rebound acid hypersecretion on withdrawal.
๐ References
๐ Revisions